The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $3.65 in the prior trading day, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $3.56, down -2.47%. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 2.29 million shares were traded. ABCL stock price reached its highest trading level at $3.685 during the session, while it also had its lowest trading level at $3.53.
Ratios:
Our goal is to gain a better understanding of ABCL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.10 and its Current Ratio is at 10.10. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.14.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1065632704 and an Enterprise Value of 712178752. For the stock, the TTM Price-to-Sale (P/S) ratio is 30.17 while its Price-to-Book (P/B) ratio in mrq is 1.10. Its current Enterprise Value per Revenue stands at 20.161 whereas that against EBITDA is -3.061.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.73, which has changed by 0.20677972 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $6.51, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -25.66%, while the 200-Day Moving Average is calculated to be -2.26%.
Shares Statistics:
The stock has traded on average 5.16M shares per day over the past 3-months and 4332450 shares per day over the last 10 days, according to various share statistics. A total of 299.01M shares are outstanding, with a floating share count of 230.61M. Insiders hold about 22.96% of the company’s shares, while institutions hold 35.89% stake in the company. Shares short for ABCL as of 1763078400 were 54443811 with a Short Ratio of 10.55, compared to 1760486400 on 53201052. Therefore, it implies a Short% of Shares Outstanding of 54443811 and a Short% of Float of 23.59.
Earnings Estimates
The market rating for AbCellera Biologics Inc (ABCL) is a result of the insights provided by 4.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.61 and -$0.71 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.69, with 3.0 analysts recommending between -$0.62 and -$0.8.
Revenue Estimates
7 analysts predict $6.28M in revenue for. The current quarter. It ranges from a high estimate of $9.28M to a low estimate of $3.95M. As of. The current estimate, AbCellera Biologics Inc’s year-ago sales were $5.1MFor the next quarter, 7 analysts are estimating revenue of $14.43M. There is a high estimate of $33.53M for the next quarter, whereas the lowest estimate is $7.58M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $39.56M, while the lowest revenue estimate was $34.22M, resulting in an average revenue estimate of $36.06M. In the same quarter a year ago, actual revenue was $28.83MBased on 7 analysts’ estimates, the company’s revenue will be $56.31M in the next fiscal year. The high estimate is $176.87M and the low estimate is $29.04M.
